| Age (Years ± SD) | Group 1 n=13 (Biologic-Naïve) 50.32 ±4.57 | Group 2 n=12 (Anti-TNFα Failed) 52±6.09 | P Value p=0.08 |
|---|---|---|---|
| Sex | |||
| Male | 1 (4%) | 1 (4%) | |
| Female | 12 (48%) | 11 (44%) | |
| DMARD numbers | |||
| One (1) used | 5 (20%) | 7 (28%) | |
| 2 ≥ more frequently used | 8 (32%) | 5 (20%) | p<0.005 |
| Duration of the disease years ± SD | 5±1.89 | 10.04 ± 3.92 | p<0.001 |
| ESR baseline (M±SD) | 47.39 ± 7.69 | 35±5.12 | p<0.001 |
| CRP baseline mg/dl: (M±SD) | 12.25±2.68 | 9±1.08 | p<0.001 |
| DAS28 baseline (M±SD) | 4.93±0.37 | 3.78±0.12 | p=0.34 |
| HAQ baseline: (M±SD) | 2.33±0,21 | 2.55±0.11 | p=0.08 |
| Rheumatoid Factor positive (%) | 11 (84.6%) | 12 (100%) | p=0.81 |
| Anti CCP positive >25 Ui/ml | 8 (61.5%) | 9 (75%) | p=0.1 |